Planned leadership changes position the Company for commercialization
Preparations on track to submit
“Replimune is preparing to bring its first oncolytic immunotherapy to patients, and I am incredibly proud to be able to lead the Company through this next phase of growth as we transition to a commercial stage company,” said
Additional changes include:
Robert Coffin , Ph.D., Founder, President andChief Research & Development Officer will move to an advisory role as Founder and Chief Scientist and will continue to serve on the Board of Directors.Paul Bullock is being appointed Chief Manufacturing Officer and will assume oversight of manufacturing and lead operations inFramingham andMilton Park in theUnited Kingdom , following the retirement ofColin Love , Ph.D., Chief Operations Officer, and co-founder, who established our manufacturing operations.Pamela Esposito , Ph.D., Chief Business Officer, andTanya Lewis , Chief Development Operations Officer, will leave their executive positions and plan to continue to lend their functional expertise in an advisory capacity.
“In 2015, Philip and I set out on a journey to develop a new class of oncolytic immunotherapies,” said
About Replimune
Forward Looking Statements
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations about the design and advancement of our clinical trials, the timing and sufficiency of our clinical trial outcomes to support potential approval of any of our product candidates, our goals to develop and commercialize our product candidates, patient enrollments in our existing and planned clinical trials and the timing thereof, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of the coronavirus as a global pandemic and related public health issues and the Russian-Ukrainian and Israel-Hamas political and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.
Investor Inquiries
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
917.548.1582
media@replimune.com
Source:
2024 GlobeNewswire, Inc., source